Drugs / PH-762
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06014086 | Nov 2023 → Dec 2025 overdue | cutaneous melanoma, cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | Phio Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 35
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Phio Pharmaceuticals Inc. | Regulatory Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma phiopharma.com ↗
Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration (FDA). |
| 2026-03-23 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement phiopharma.com ↗ |
| 2026-03-05 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update phiopharma.com ↗
Concluding the Phase 1b study with favorable safety, tolerability and pathology data, advancing the CMC and toxicology initiatives while extending our cash runway into 2027 are noteworthy milestones on our continuing pathway to potential approval. |
| 2026-02-10 | Phio Pharmaceuticals Inc. | Results Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial phiopharma.com ↗
No dose-limiting toxicities or serious adverse events have been reported for any of the 22 enrolled patients who completed 4 intratumoral injections of PH-762 and have been followed through at least 4 weeks after the final injection. |
| 2026-01-20 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial phiopharma.com ↗
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders |
| 2025-12-23 | Phio Pharmaceuticals Inc. | Regulatory Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 phiopharma.com ↗
The company will begin a toxicology study, which is required by the FDA prior to commencing a human pivotal trial. |
| 2025-11-13 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update phiopharma.com ↗
To date, pathologic results for the fifth and final cohort were as follows: 100% tumor clearance in one of three patients, > 90% clearance in the second patient, and > 50% clearance in the third patient at Day 36. |
| 2025-11-03 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial phiopharma.com ↗
The cumulative pathologic response in 16 patients with cSCC include six with a complete response (100% clearance), two with a near complete response (> 90% clearance) and two with a partial response (> 50% clearance). |
| 2025-07-25 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort phiopharma.com ↗
Phio announced today that pathologic results are available for four of the five patients treated in the fourth cohort. |
| 2025-06-25 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort phiopharma.com ↗
As with the previous three cohorts, injections were well-tolerated and there were no dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent adverse reactions reported. |
| 2025-05-07 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial phiopharma.com ↗
Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (cSCC) treated in the third dose cohort. |
| 2025-04-09 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort phiopharma.com ↗
Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio’s Phase 1b clinical trial (NCT 06014086) for Phio’s lead product candidate, PH-762. |
| 2025-03-10 | Phio Pharmaceuticals Inc. | Results American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical’s Clinical Research at 2025 Annual Meeting phiopharma.com ↗
The fourth patient in this cohort exhibited stable disease, having not progressed. |
| 2025-01-13 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 phiopharma.com ↗
Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma. |
| 2024-12-19 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 phiopharma.com ↗ |
| 2024-12-12 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Publication in Frontiers in Immunology phiopharma.com ↗
The article presents preclinical proof-of-concept data for PH-762, an INTASYL compound designed to silence PD-1, is currently in clinical development for advanced cutaneous malignancies. |
| 2024-11-19 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study phiopharma.com ↗
one patient with cutaneous squamous cell carcinoma achieved a complete response (100% tumor clearance) |
| 2024-11-07 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) phiopharma.com ↗
Complete response (100% tumor clearance) reported for 1 patient with cutaneous squamous cell carcinoma; |
| 2024-10-07 | Phio Pharmaceuticals Inc. | Results Phio Announces Data Showcasing INTASYL’s Role in Helping Immune Cells Target and Kill Cancer Cells phiopharma.com ↗
INTASYL compound PH-762 silences PD-1, improving therapeutic efficacy in vivo. |
| 2024-05-28 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762 phiopharma.com ↗
There have been no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the initial cohort receiving intratumoral PH-762. |
| 2024-05-16 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) phiopharma.com ↗
In a murine model, mPH-762 was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth. |
| 2024-04-22 | Phio Pharmaceuticals Inc. | Results Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells phiopharma.com ↗
Intratumoral injection of murine PH-762 (mPH-762) significantly inhibits tumor growth in murine tumor models and is well tolerated |
| 2023-05-16 | Phio Pharmaceuticals Inc. | Regulatory Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas phiopharma.com ↗
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to proceed with a clinical trial of Phio’s lead product candidate, PH-762. |
| 2023-04-17 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity phiopharma.com ↗
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a hepatocellular carcinoma model provides insight into the mechanism by which locally administered mouse-targeted PH-762 (mPH-762) exerts systemic anti-tumor efficacy (“abscopal effect”). |
| 2023-02-10 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification phiopharma.com ↗
The safety data review disclosed no dose-limiting toxicity, and no drug-related severe adverse events or serious adverse events, and the DMC recommended proceeding to the enrollment of the subsequent dose cohort, as intended per the study protocol. |
| 2023-01-06 | Phio Pharmaceuticals Inc. | Regulatory Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx’s Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors phiopharma.com ↗
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced their clinical development partner, AgonOx, Inc. has received confirmation from the FDA that their planned Phase 1 clinical trial in patients with advanced solid tumors may proceed. |
| 2022-11-10 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th phiopharma.com ↗ |
| 2022-09-22 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference phiopharma.com ↗
These data demonstrate that PH-762 enhances the population of T cells that have more stem-like characteristics. |
| 2022-04-18 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer phiopharma.com ↗
Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model |
| 2022-01-11 | Phio Pharmaceuticals Inc. | Regulatory Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma phiopharma.com ↗
The Company was granted the clinical trial authorization (CTA) by the French National Agency for the Safety of Medicines and Health Products (ANSM – L’Agence nationale de sécurité du médicament et des produits de santé) to proceed with a first-in-human clinical trial for PH-762 to treat patients with melanoma at the Gustave Roussy Institute. |
| 2021-11-12 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting phiopharma.com ↗
The data from this study in an in vivo hepatocarcinoma model shows that PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response. |
| 2021-05-11 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells phiopharma.com ↗
Compared to untreated HER2CART cells, HER2CART cells treated with PH-762 showed a statistically significant and durable inhibition of tumor growth. |
| 2021-04-10 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 phiopharma.com ↗ |
| 2020-05-29 | Phio Pharmaceuticals Inc. | Results Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity phiopharma.com ↗
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive data from in vivo studies that show strong antitumoral efficacy with several of its INTASYL pipeline programs, including PH-762, PH-894 and PH-804. |
| 2020-03-31 | Phio Pharmaceuticals Inc. | Results Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform’s Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth phiopharma.com ↗
These studies show that a local administration of mPH-762 or PH-894 through intra-tumoral injection resulted in potent anti-tumoral effects. |
All press releases naming this drug 51 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PH-762 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06014086 ↗ |
| Action | Inhibit | “PH-762 can inhibit the immune checkpoint PD-1 in the tumor” NCT06014086 ↗ |
| Route | Other | “intratumoral injections of PH-762” NCT06014086 ↗ |